Variational AI has developed an AI-based platform to rapidly generate novel multi-target kinase inhibitors focused on solid tumor indications. The platform is able to optimize selectivity in addition to binding affinity, PK, toxicity, and synthesizability simultaneously using multiproperty optimization and generate novel compounds from new areas of chemical space in a matter of weeks.

Founded in 2019, Variational AI is currently collaborating with partners on novel kinase targets and will develop its own internal pipeline of next-generation kinase inhibitors. Variational AI is post-seed and pre-series A with investors from Seattle and Silicon Valley. The leadership team combines true machine learning scientists from MIT, Caltech, Google, Microsoft and D-Wave Systems with drug discovery and development veterans with 124 patents, 11 drugs licensed to Roche, AstraZeneca, Merck, and BMS.